

1 Macrolides inhibit *Fusobacterium nucleatum*-induced MUC5AC induction in  
2 human airway epithelial cells

3

4 Kentaro Nagaoka <sup>a,b,d</sup>, MD, Katsunori Yanagihara <sup>a,b,\*</sup>, MD, PhD, Yosuke  
5 Harada <sup>a,b</sup>, MD, Koichi Yamada <sup>a,b</sup>, MD, Yohei Migiyama <sup>a,b</sup>, MD, Yoshitomo  
6 Morinaga <sup>a,b</sup>, MD, PhD, Koichi Izumikawa <sup>b</sup>, MD, PhD, Hiroshi Takeya <sup>b</sup>, MD,  
7 PhD, Masaharu Nishimura<sup>d</sup>, MD, PhD, and Shigeru Kohno <sup>b,c</sup>, MD, PhD

8

9 <sup>a</sup>Department of Laboratory Medicine and <sup>b</sup>Second Department of Internal  
10 Medicine, Nagasaki University Graduate School of Biomedical Sciences,  
11 Nagasaki, Japan; <sup>c</sup>Global COE Program, Nagasaki University, Nagasaki,  
12 Japan

13 <sup>d</sup>First Department of Internal Medicine, Hokkaido University Hospital,  
14 Hokkaido, Japan

15

16 \*Corresponding author:

17 Katsunori Yanagihara

18 Department of Laboratory Medicine, Nagasaki University Graduate School

19 of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.

20 Tel: +81-95-819-7418; Fax: +81-95-819-7257

21 E-mail: [k-yanagi@nagasaki-u.ac.jp](mailto:k-yanagi@nagasaki-u.ac.jp)

22

23 Funding/support: This research was funded by the Department of

24 Laboratory Medicine and Second Department of Internal Medicine,

25 Nagasaki University Graduate School of Biomedical Sciences, Nagasaki,

26 Japan. This study was not sponsored by any grants, gifts, or fellowships.

27

28 Running title: Macrolides inhibit Fusobacterium-induced MUC5AC

29 Keywords: mucin production, anaerobe, periodontitis, macrolides

30

31 Abstract 225 words

32 Text 2753 words

33

34

35

36

37 **Abstract**

38 *Fusobacterium nucleatum* (Fn) is one of the most common anaerobic bacteria  
39 in periodontitis and is responsible for several extra-oral infections including  
40 respiratory tract diseases. In this study, we examined whether Fn induces  
41 mucin secretion in airway epithelial cells. We also examined the effects of  
42 macrolides on the Fn-induced mucus production compared with other  
43 antibiotics that exert anti-anaerobic activities. MUC5AC production in  
44 bronchial epithelial cells after stimulation with culture supernatants (Sup)  
45 of Fn was analyzed by performing enzyme-linked immunosorbent assay and  
46 quantitative RT-PCR. The cell-signaling pathway of Fn Sup stimulation was  
47 also analyzed by performing Western blotting. For inhibition studies, cells  
48 were treated with azithromycin, clarithromycin, clindamycin (CLDM), and  
49 metronidazole (MTZ). The Fn Sup-induced NCI-H292 cells to express  
50 MUC5AC at both the protein levels and the mRNA level in both a time- and  
51 dose-dependent manner. Macrolides inhibited Fn Sup-induced MUC5AC  
52 production, while CLDM and MTZ were less effective. Fn Sup induced the  
53 phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, and this  
54 induction was suppressed by macrolides. Fn Sup-induced MUC5AC

55 production was blocked by the ERK pathway inhibitor U0126. Fn is likely to  
56 contribute to excessive mucin production, which suggest that periodontitis  
57 may correlate with the pathogenesis of chronic respiratory tract infection.  
58 The macrolides seem to reduce this mucin production and might represent  
59 an additional therapeutic intervention for Fn respiratory tract infections  
60 other than CLDM and MTZ.

61

62

63

64

65

66

67

68

69

70

71

72

73 **Introduction**

74 Although mucus secretion is useful for host protection against pathogens and  
75 irritants, mucus hypersecretion causes airway obstruction and impairment  
76 of gas exchange in chronic inflammatory lung disease including asthma,  
77 cystic fibrosis, diffuse panbronchiolitis (DPB), and COPD. Therefore,  
78 preventing mucus overproduction is beneficial for these diseases. Many  
79 factors, including bacterial infection, that contribute to mucus  
80 hypersecretion have been previously described (1, 2). However, there are few  
81 studies that focus on the relationship between oral bacterium infection and  
82 mucus hyper secretion.

83 Poor oral hygiene has been suggested to be a risk factor of respiratory  
84 disease (3), and several studies indicate that oral care reduces the incidence  
85 and mortality of pneumonia (4–7). However, the detailed mechanisms that  
86 described the poor oral hygiene and respiratory tract disease relationship are  
87 not fully understood.

88 *Fusobacterium nucleatum* (Fn) is a common anaerobic bacterium of  
89 periodontitis, which is also found as etiologic pathogen of respiratory  
90 anaerobic infection (8). As the important virulence factor, Fn produces high

91 amounts of butyric acid during anaerobic glycolysis. Recently, several reports  
92 indicated that butyric acid plays a critical role in a variety of diseases,  
93 including HIV infection (9, 10), and ulcerative colitis (11). Considering the  
94 effect of oral bacterium on respiratory tract disease, the aspiration of  
95 products originating from periodontal tissues has been suggested as a  
96 possible mechanism of the effects on respiratory tract (12). With respect to  
97 the frequency of aspiration, Marik PE et al. reported that approximately half  
98 of all healthy adults aspirate small amount of oropharyngeal secretions  
99 during sleep (13). On the basis of these reports, we expect that Fn, a major  
100 periodontal bacterium, might have a pathogenic effect on airway epithelium  
101 cells via aspiration of its products.

102 In this study, we examined the effects of Fn culture supernatant (Sup) on  
103 airway epithelium cell mucus secretion. The major macromolecular  
104 constituents of mucus are the mucin glycoproteins. Among mucin proteins,  
105 we focused on MUC5AC, the major core protein of mucin secreted from the  
106 airway surface epithelium.

107 We also examined the effects of the macrolides, azithromycin (AZM) and  
108 clarithromycin (CAM), on the Fn Sup-induced mucus production and

109 compared their effects to other antibiotics which have anti-anaerobic  
110 activities (e.g., clindamycin (CLDM) and metronidazole (MTZ)). Macrolide  
111 antibiotics have been shown to be effective for the treatment of chronic  
112 airway diseases (14, 15). The beneficial effects of macrolide therapy are not  
113 only related to its bactericidal properties, but extend to its  
114 immune-modulating/anti-inflammatory effects (16). We previously reported  
115 that macrolides inhibit MUC5AC production induced by several factors  
116 (*Pseudomonas aeruginosa* autoinducer (17), lipopolysaccharide (18),  
117 Nontypeable *Haemophilus influenza* (19), *Chlamydomphila pneumonia* (20))  
118 in human lung epithelial cells, and found that these mucin reduction by  
119 macrolides relate to several intracellular signal transduction, including  
120 extracellular signal-regulated kinase (ERK) 1/2 phosphoryration (17, 18),  
121 NFκB activation (17, 20) or AP-1 activation (19). As macrolide have no  
122 bactericidal activities against Fn, the effect on mucin production compared  
123 with CLDM and MTZ would provide insight concerning the treatment of Fn  
124 respiratory tract infections.

125 The aims of this study were to determine whether Fn Sup possesses  
126 stimulatory action on the production of MUC5AC, and to clarify whether

127 macrolides have different effect on Fn Sup-induced MUC5AC production as  
128 compared to CLDM and MTZ.

129

## 130 **Materials and Methods**

### 131 **Fn strain and culture conditions to obtain Fn Sup**

132 A clinical isolate of Fn (strain FNU-191), maintained as a stock culture in the  
133 Department of Laboratory Medicine, Nagasaki University Hospital,  
134 Nagasaki, Japan, was used in this study. We identified the strain by PCR  
135 amplification and sequencing analysis of the 16S rRNA gene. The  
136 supernatant was obtained as described previously (10). Briefly, the Fn strain  
137 was cultured on PV Brucella HK Agar (Kyokuto Pharmaceutical Industrial  
138 Co., Tokyo, Japan) for 48 h in an anaerobic condition, and then scraped and  
139 suspended in modified GAM broth (Nissui Pharmaceutical Industrial Co.,  
140 Tokyo, Japan) and cultured in anaerobic chamber for 48 h. The supernatant  
141 was then collected by centrifugation at 10,000 rpm for 50 min at 4 °C to  
142 remove the bacteria and then filter-sterilized through a 0.22 µm pore  
143 membrane filter (Millipore, Bedford, MA, USA). In the preliminary  
144 experiments, we examined MUC5AC induction of 6 *Fusobacterium* spp.



145 strains including the reference strain (ATCC 10953). We found that all the  
146 supernatant of *Fusobacterium* spp. similarly induced MUC5AC production  
147 at a 1:39–1:79 dilution and inhibited MUC5AC production at a 1:4–1:19  
148 dilution. In order to test for clinical relevancy, we selected the clinically  
149 isolated strain of Fn for the further experiments. Therefore, all the  
150 experiments in this study were performed using the F2 strain.

### 151 **Cell culture**

152 The NCI-H292 (Human airway epithelial) cell line was cultured in RPMI  
153 1640 medium supplemented with 10% fetal bovine serum, 100 U of  
154 penicillin/ml, and 100 µg of streptomycin/ml. The cells were grown at 37 °C  
155 with 5% CO<sub>2</sub> in fully humidified air. For the MUC5AC production studies,  
156 cells were exposed to Fn Sup for RT-PCR, enzyme-linked immunosorbent  
157 assay (ELISA), or Western Blotting. For controls, the cells were incubated  
158 with GAM broth.

### 159 **Preparations of antibiotic dilutions**

160 AZM and CAM were provided by Pfizer (Tokyo, Japan) and Taisho-Toyama  
161 (Tokyo, Japan), respectively. Clindamycin and metronidazole were obtained  
162 from Nacalai Tesque (Kyoto, Japan). Each drug, except MTZ, was diluted in

163 DMSO at final concentrations of 1-100 µg/ml for the following experiments.

164 Only MTZ was diluted in acetic acid.

#### 165 **ELISA**

166 The NCI-H292 cells were plated in a 24-well plate, and MUC5AC protein

167 was measured by performing ELISA as previously described (17–20). After

168 Fn Sup stimulation, the culture medium was collected as the cell

169 supernatant. This supernatant was then incubated at 40 °C in a 96-well

170 plate until dry. The plated culture were blocked with 2% bovine serum

171 albumin for 1 h at room temperature and were then incubated with the

172 anti-MUC5AC antibody diluted in PBS containing 0.05% Tween 20 for 1 h.

173 Horseradish peroxidase (HRP)-conjugated anti-goat IgG was then dispensed

174 into each well. After 1 h, the plates were washed 3 times with PBS. Color

175 was developed using a 3,3', 5, 5'-tetramethyl-benzine-peroxidase solution,

176 and the reaction was stopped by the addition of 2 N H<sub>2</sub>SO<sub>4</sub>. Absorbance was

177 read at 450 nm.

#### 178 **Inhibition of cell signaling activity**

179 ERK inhibitor U0126, p38 mitogen-activated protein kinase (MAPK)

180 inhibitor SB203580 and specific NFκB inhibitor caffeic acid phenethyl ester

181 (CAPE) were used at concentrations 10  $\mu$ M (in DMSO stock solution). Cells  
182 were treated with these inhibitors 30 min before Fn Sup stimulation. Control  
183 cultures were treated with an equal volume of DMSO. All the inhibitors were  
184 purchased from Calbiochem (San Diego, California).

### 185 **RT-PCR**

186 We evaluated MUC5AC mRNA expression by RT-PCR as described  
187 previously (17–20). Total RNA was extracted from NCI-H292 cells cultured  
188 in 6 well plates using QuickGene-Mini80 and QuickGene RNA cultured cell  
189 kits (FUJIFILM Co., Tokyo, Japan), according to the manufacturer's  
190 instructions. Total RNA (1  $\mu$ g) was reverse transcribed into cDNA using  
191 oligo(dT) primers and SuperScript III reverse transcriptase (Invitrogen,  
192 Carlsbad, CA), and was then treated with RNaseH. To quantify the  
193 expression of the MUC5AC gene, PCR primers and Taqman probes were  
194 designed and used as reported previously (Forward primer,  
195 5'-CAGCCACGTCCCCTTCAATA-3'; Reverse primer,  
196 5'-ACCGCATTTGGGCATCC-3'; Taqman probe,  
197 5'-6-FAM-CCACCTCCGAGCCCGTCACTGAG-TAMRA-3') (21). MUC5AC  
198 was amplified for 40 cycles (15 s at 95  $^{\circ}$ C, and 30 s at 60  $^{\circ}$ C) using a

199 LightCycler system. To normalize MUC5AC expression, human  
200 porphobilinogen deaminase (hPBGD) was also measured using an hPBGD  
201 primer set (Roche Diagnostics GmbH, Mannheim, Germany) according to the  
202 manufacturer's instructions. Data are presented as a ratio of hPBGD.

### 203 **Western blot analysis**

204 Proteins were separated by performing reducing sodium dodecyl sulfate 12%  
205 polyacrylamide gel electrophoresis and transferred to nitrocellulose  
206 membranes (Amersham Pharmacia Biotech, Piscataway, N.J.) in a solution  
207 of 20% methanol, 25 mM Tris-HCl, 0.2 M glycine. Nonspecific binding was  
208 blocked by incubating the membranes with 10% fetal bovine serum in  
209 Tris-buffered saline with 0.1% Tween 20 for 1 h at room temperature.  
210 Immunoreactive proteins were detected by incubating the membrane with  
211 rabbit anti-human ERK1/2, anti-phospho-ERK1/2, anti-human p38,  
212 anti-phospho-p38, anti-human I- $\kappa$ B, or anti-phospho-I- $\kappa$ B antibodies (each  
213 at 1:1000) overnight at 4 °C. Between each step, the membrane were washed  
214 3 times for 15 min each with Tris-buffered saline that contained 0.1% Tween  
215 20. Subsequently, the membranes were incubated for 1 h with anti-rabbit  
216 immunoglobulin G conjugated to HRP (1:10,000), rewashed, and developed

217 with enhanced chemiluminescence reagents (Amersham Pharmacia  
218 Biotech).

## 219 **Statistical analysis**

220 All data were expressed as the mean and standard error of the mean (SEM).  
221 Differences were examined for statistical significance by using the one-way  
222 analysis of variance for comparisons involving more than 2 groups and the  
223 Student's t test for comparisons between 2 groups. *P* values less than 0.05  
224 were considered statistically significant.

225

## 226 **Results**

### 227 **Fn Sup up-regulates MUC5AC gene and protein expression**

228 To determine whether Fn Sup can induce mucin production in NCI-H292  
229 cells, we evaluated MUC5AC expression at both the mRNA and the protein  
230 level after the addition of Fn Sup. Stimulation of the NCI-H292 cells with  
231 GAM broth (1:9 dilution) had small effect on MUC5AC production compared  
232 to the stimulation with RPMI medium alone. However, the amounts of  
233 MUC5AC were significantly larger in Fn-Sup stimulation at the 1:79 to  
234 1:319 dilution compared to GAM broth stimulation. The protein level (Fig.

235 1A) and mRNA expression (Fig. 1B) were maximal at the 1:79 dilution. The  
236 up-regulation of MUC5AC by the addition of Fn-Sup at a 1:79 dilution  
237 occurred in a time-dependent manner, and the protein level (Fig. 2A) was  
238 maximal at 24 h after stimulation. The mRNA expression level (Fig. 2B)  
239 increased until 12 h and decreased at 18 h after stimulation. The maximal  
240 mRNA expression was obtained at 10 h after stimulation (Data not showed),  
241 thus, we analyzed all other experiments concerning MUC5AC mRNA at 10 h  
242 after stimulation.

#### 243 **Fn Sup phosphorylates ERK**

244 MAPKs are important signals related to MUC5AC production. To examine  
245 the cell-signaling pathway of Fn Sup stimulation in NCI-H292 cells, we  
246 examined the phosphorylation of kinase by western blotting (Fig. 3). We  
247 analyzed kinase phosphorylation in both GAM broth and Fn Sup activated  
248 cells at 0–720 min after stimulation. Compared to GAM broth (Fig. 3A),  
249 maximal ERK phosphorylation of Fn Sup-activated cells was observed 240  
250 min after stimulation (Fig. 3B), while ERK phosphorylation of GAM  
251 broth-activated cells was mainly observed 480 min after stimulation. We also  
252 performed an inhibition assay of the cell-signaling pathway (Fig. 4). The

253 ERK inhibitor U0126 effectively suppressed the MUC5AC protein  
254 production compared to the untreated cells. Although the NFκB inhibitor  
255 CAPE and the p38 MAP kinase inhibitor SB203580 also suppressed the  
256 MUC5AC production, apparent phosphorylation of IκB or p38 could not be  
257 found by Western blotting.

### 258 **Macrolides inhibits MUC5AC production by Fn Sup activated cells**

259 To evaluate the effect of the macrolides CLDM and MTZ on Fn Sup-induced  
260 MUC5AC production, we treated cells with a 1–100 μg/ml concentration of  
261 each drug. Since CAM could not dissolved in 100 μg/ml, we examined its  
262 affects at the 1–50 μg/ml concentration. As shown in Fig. 5A and B, the  
263 macrolides significantly reduced MUC5AC protein level at the 1–100 μg/ml  
264 concentration in dose-dependent manner. CLDM significantly reduced  
265 MUC5AC protein level at the 100 μg/ml concentration, and MTZ did not  
266 reduce MUC5AC protein at any concentration. At the maximum dosage of  
267 each drug, we also examined the effect on MUC5AC mRNA expression. For  
268 controls and untreated group, the cells were also stimulated with same  
269 amount of DMSO or acetic acid contained in the drug dilutions. Since only  
270 MTZ needed to be dissolved with acetic acid, the evaluation of MTZ was

271 examined separately.

272 As shown in Fig. 6, the macrolides significantly reduced the mRNA  
273 expression level of MUC5AC, while no significant reduction was found with  
274 CLDM and MTZ.

275 **Macrolides down-regulate the phosphorylation of ERK in Fn Sup activated**  
276 **NCI-H292 cells**

277 In order to investigate the potential role for the Fn Sup-activated  
278 cell-signaling pathway of macrolides, CLDM and MTZ, we examined the  
279 phosphorylation of ERK, the most significantly up-regulated signaling  
280 pathway during Fn Sup induced activation. As shown in Fig. 7A, the  
281 macrolides suppressed the phosphorylation of ERK compared to Fn Sup  
282 stimulation alone and CLDM. MTZ did not affect the detection level  
283 compared to stimulation alone (Fig. 7B).

284

285 **Discussion**

286 The present study is the first to demonstrate that the product of Fn induces  
287 MUC5AC via phosphorylation of ERK1/2. We also found that macrolides  
288 inhibit MUCAC production induced by the products of Fn, while CLDM and



289 MTZ were less effective.

290 Fn is a gram-negative anaerobic species of the phylum *Fusobacteria*,  
291 numerically dominant in dental plaque biofilms, and important in biofilm  
292 ecology and human infectious diseases (8). Fn is one of the most common oral  
293 species isolated from extra-oral infections of the blood, brain, chest, lung,  
294 liver, joints, abdomen, obstetrical and gynecological infections, and abscesses.  
295 In addition to these infections, the products of Fn have been recently  
296 reported to reactivate the latently-infected HIV-1 virus (10). Among the  
297 components of its supernatant, butyric acid is thought to inhibit the catalytic  
298 action of histone deacetylases and induces transcription of silenced genes  
299 including the HIV-1 provirus (9). Interestingly, butyric acid contained in  
300 *Fusobacterium* species has been reported to be involved in the pathogenesis  
301 of ulcerative colitis by inducing cell toxicity (11). Considering these  
302 discoveries, Fn is an increasingly significant pathogen with potential to have  
303 societal impact on human infections. However, there are few descriptive data  
304 of Fn concerning its relationship with respiratory tract diseases.

305 In the present study, we demonstrated that the product of Fn have additive  
306 effects on mucin production in airway epithelial cells. Interestingly, high

307 concentrations of Fn Sup inhibited MUC5AC production, while relatively low  
308 concentration of Fn Sup increased MUC5AC production. This suggests that  
309 aspiration of saliva containing even low concentration of Fn products may  
310 cause hypersecretion in the associated disease. The reason why high  
311 concentration of Fn Sup inhibits MUC5AC production is not clear, however,  
312 as low dose concentration of Fn products may be found more frequently in  
313 oral contents, Fn may play a negative role in the pathogenesis of chronic  
314 respiratory tract infections via aspiration of its products.

315 In this study, we also demonstrated that macrolides reduces MUC5AC  
316 production induced by Fn Sup. Long-term treatment with macrolide  
317 antibiotics is considered to be effective in DPB and CF due to their  
318 anti-inflammatory effects rather than antimicrobial effects (14, 15). In  
319 addition, a multicenter, double-blind, randomized clinical trial conducted in  
320 Greece showed that intravenous CAM administration for 3 consecutive days  
321 improves the length of illness and mortality of VAP (22), which indicate the  
322 macrolide might also be beneficial for acute infections with short-term  
323 treatment. However, although CLDM and MTZ are both known to reduce  
324 cytokine production induced by certain bacterial component or products

325 (23–25), the existence of anti-inflammatory effects of CLDM and MTZ,  
326 similar to those of macrolides, remains uncertain. In the present study,  
327 CLDM and MTZ did not exhibit a concentration-dependent reduction of Fn  
328 Sup-induced MUC5AC production compared to macrolides. To investigate  
329 the reason for this discrepancy with the effect of CLDM and MTZ against Fn  
330 Sup-induced MUC5AC production, we examined the MAPK signal  
331 transduction pathway. Among a variety of signal transduction molecules,  
332 MAPK has been shown to play an important role in mucin production (26). In  
333 this study, Fn Sup induced the phosphorylation of ERK1/2. Enhanced  
334 MUC5AC protein production was also strongly reduced by an inhibitor of  
335 MEK (U0126). This result indicates that Fn Sup mainly up-regulates  
336 MU5AC production through MAPK transduction. However, AZM and CAM  
337 inhibited phosphorylation of ERK1/2 induced by Fn Sup, while CLDM and  
338 MTZ did not. Taken together, macrolides are effective to prevent MU5AC  
339 production by different mechanisms from CLDM or MTZ. Thus, stimulation  
340 with Fn Sup would be affected by AZM and CAM up-stream of ERK1/2.  
341 The main limitation of our study is that modified GAM broth also had  
342 positive effect on MUC5AC production and ERK 1/2 up-regulation. However,

343 the effect of GAM broth alone on MUC5AC production was significantly  
344 small compared to Fn Sup stimulation. ERK 1/2 phosphorylation showed a  
345 unique patterned independent of Fn Sup treatment. Although Fn Sup  
346 induced phosphorylation of ERK 1/2 at 4 h after stimulation, GAM broth did  
347 so at 8 h. Although we could verify Fn potential for mucin production in this  
348 study, further study is needed to identify a more detailed mechanism of  
349 Fn-induced MUC5AC production that focuses on particular components of  
350 Fn products, such as butyric acid.

351 Our results provide novel evidence that *F. nucleatum* may induce mucus  
352 hypersecretion, which suggests that periodontitis may exhibit a relationship  
353 with the pathogenesis of chronic respiratory tract infection. Our study also  
354 shows that macrolides reduce this mucin production and may act as an  
355 additional therapeutic intervention unique from CLDM and MTZ.

356

### 357 **Acknowledgements**

358 All authors have contributed to the design, data collection, analysis,  
359 preparation, critical revision of the manuscript. The authors have no  
360 potential conflicts of interest exist with any companies/organizations whose

361 products or services may be discussed in this article.

362

363 **References**

- 364 1. **Dohrman A, Miyata S, Gallup M, Li JD, Chapelin C, Coste A, Escudier E,**  
365 **Nadel J, Basbaum C.** 1998. Mucin gene (MUC 2 and MUC 5AC) upregulation  
366 by Gram-positive and Gram-negative bacteria. *Biochim. Biophys. Acta.*  
367 **1406:251-9.**
- 368 2. **Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y.** 2003. In vivo  
369 and in vitro effects of macrolide antibiotics on mucus secretion in airway  
370 epithelial cells. *Am. J. Respir. Crit. Care Med.* **168:581-7.**
- 371 3. **Sjögren P, Nilsson E, Forsell M, Johansson O, Hoogstraate J.** 2008. A  
372 systematic review of the preventive effect of oral hygiene on pneumonia and  
373 respiratory tract infection in elderly people in hospitals and nursing homes:  
374 effect estimates and methodological quality of randomized controlled trials. *J.*  
375 *Am. Geriatr. Soc.* **56:2124-30.**
- 376 4. **Adachi M, Ishihara K, Abe S, Okuda K, Ishikawa T.** 2002. Effect of  
377 professional oral health care on the elderly living in nursing homes. *Oral*  
378 *Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* **94:191-5.**

379 5. **DeRiso AJ 2nd, Ladowski JS, Dillon TA, Justice JW, Peterson AC.** 1996.  
380 Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total  
381 nosocomial respiratory infection and nonprophylactic systemic antibiotic use  
382 in patients undergoing heart surgery. *Chest.* **109**:1556-61.

383 6. **Yoneyama T, Yoshida M, Matsui T, Sasaki H.** 1999. Oral care and  
384 pneumonia. *Lancet.* **354**:515.

385 7. **Yoneyama T, Yoshida M, Ohru T, Mukaiyama H, Okamoto H, Hoshiba K,**  
386 **Ihara S, Yanagisawa S, Ariumi S, Morita T, Mizuno Y, Ohsawa T, Akagawa Y,**  
387 **Hashimoto K, Sasaki H; Oral Care Working Group.** Oral care reduces  
388 pneumonia in older patients in nursing homes. 2002. *J. Am. Geriatr. Soc.*  
389 **50**:430-3.

390 8. **Signat B, Roques C, Poulet P, Duffaut D.** 2011. *Fusobacterium nucleatum*  
391 in periodontal health and disease. *Curr. Issues Mol. Biol.* **13**:25-36.

392 9. **Imai K, Ochiai K.** 2011. Role of histone modification on transcriptional  
393 regulation and HIV-1 gene expression: possible mechanisms of periodontal  
394 diseases in AIDS progression. *J Oral Sci.* **53**:1-13.

395 10. **Imai K, Yamada K, Tamura M, Ochiai K, Okamoto T.** 2012. Reactivation  
396 of latent HIV-1 by a wide variety of butyric acid-producing bacteria. *Cell Mol.*

397 Life Sci. **69**:2583-92.

398 11. **Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N.** 2003.

399 Induction of experimental ulcerative colitis by *Fusobacterium varium*

400 isolated from colonic mucosa of patients with ulcerative colitis. Gut.

401 **52**:79-83.

402 12. **Azarpazhooh A, Leake JL.** 2006. Systematic review of the association

403 between respiratory diseases and oral health. J. Periodontol. **77**:1465-82.

404 13. **Marik PE, Kaplan D.** 2003. Aspiration pneumonia and dysphagia in the

405 elderly. Chest. **124**:328-36.

406 14. **Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M.** 1998. Improvement

407 of survival in patients with diffuse panbronchiolitis treated with low-dose

408 erythromycin. Am. J. Respir. Crit. Care Med. **157**:1829-1832.

409 15. **Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL,**

410 **Cibene DA, Coquillet S, Fieberg AY, Accurso FJ, Campbell PW III.** 2003.

411 Azithromycin in patients with cystic fibrosis chronically infected with

412 *Pseudomonas aeruginosa*: a randomized controlled trial. JAMA.

413 **290**:1749-1756.

414

- 415 16. **Giamarellos-Bourboulis EJ.** 2008. Immunomodulatory therapies for  
416 sepsis: unexpected effects with macrolides. *Int. J. Antimicrob. Agents.* **32**  
417 Suppl 1:39-43.
- 418 17. **Imamura Y, Yanagihara K, Mizuta Y, Seki M, Ohno H, Higashiyama Y,**  
419 **Miyazaki Y, Tsukamoto K, Hirakata Y, Tomono K, Kadota J, Kohno S.** 2004.  
420 Azithromycin inhibits MUC5AC production induced by the *Pseudomonas*  
421 *aeruginosa* autoinducer N-(3-Oxododecanoyl) homoserine lactone in  
422 NCI-H292 Cells. *Antimicrob. Agents Chemother.* **48**:3457-3461.
- 423 18. **Ishimoto H, Mukae H, Sakamoto N, Amenomori M, Kitazaki T, Imamura**  
424 **Y, Fujita H, Ishii H, Nakayama S, Yanagihara K, Kohno S.** 2009. Different  
425 effects of telithromycin on MUC5AC production induced by human  
426 neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with  
427 azithromycin and clarithromycin. *J. Antimicrob. Chemother.* **63**:109-14.
- 428 19. **Araki N, Yanagihara K, Morinaga Y, Yamada K, Nakamura S, Yamada Y,**  
429 **Kohno S, Kamihira S.** 2010. Azithromycin inhibits nontypeable *Haemophilus*  
430 *influenzae*-induced MUC5AC expression and secretion via inhibition of  
431 activator protein-1 in human airway epithelial cells. *Eur. J. Pharmacol.*  
432 **644**:209-214.



433 20. **Morinaga Y, Yanagihara K, Miyashita N, Seki M, Izumikawa K, Kakeya**  
434 **H, Yamamoto Y, Mukae H, Yamada Y, Kohno S, Kamihira S.** 2009.  
435 Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction  
436 by *Chlamydomytila pneumoniae* in airway epithelial cells. *Pulm. Pharmacol.*  
437 *Ther.* **22**:580-586.

438 21. **Inoue D, Yamaya M, Kubo H, Sasaki T, Hosoda M, Numasaki M, Tomioka**  
439 **Y, Yasuda H, Sekizawa K, Nishimura H, Sasaki H.** 2006. Mechanisms of  
440 mucin production by rhinovirus infection in cultured human airway  
441 epithelial cells. *Respir. Physiol. Neurobiol.* **154**:484-499.

442 22. **Giamarellos-Bourboulis EJ, Pechère JC, Routsis C, Plachouras D, Kollias**  
443 **S, Raftogiannis M, Zervakis D, Baziaka F, Koronaios A, Antonopoulou A,**  
444 **Markaki V, Koutoukas P, Papadomichelakis E, Tsaganos T, Armaganidis A,**  
445 **Koussoulas V, Kotanidou A, Roussos C, Giamarellou H.** 2008. Effect of  
446 clarithromycin in patients with sepsis and ventilator-associated pneumonia.  
447 *Clin. Infect. Dis.* **46**:1157-1164.

448 23. **Lappin E, Ferguson AJ.** Gram-positive toxic shock syndromes. 2009.  
449 *Lancet Infect. Dis.* **9**:281-290.

450 24. **Pichereau S, Moran JJ, Hayney MS, Shukla SK, Sakoulas G, Rose WE.**

451 2012. Concentration-dependent effects of antimicrobials on *Staphylococcus*  
452 *aureus* toxin-mediated cytokine production from peripheral blood  
453 mononuclear cells. *J. Antimicrob. Chemother.* **67**:123-129.

454 25. **Rizzo A, Paolillo R, Guida L, Annunziata M, Bevilacqua N, Tufano MA.**  
455 2010. Effect of metronidazole and modulation of cytokine production on  
456 human periodontal ligament cells. *Int. Immunopharmacol.* **10**:744-750.

457 26. **Selsted ME, Ouellette AJ.** 2005. Mammalian defensins in the  
458 antimicrobial immune response. *Nat. Immunol.* **6**:551-557.

459

#### 460 **Figure Legends**

461 Fig. 1. Dose-dependent effect of *Fusobacterium nucleatum* culture  
462 supernatant (FnSup) on MUC5AC expression. Confluent NCI-H292 cells  
463 were stimulated using modified GAM medium (1:9 dilution), or various  
464 concentrations of Fn Sup (dilution ratio, from 1:319 to 1:9). (A) MUC5AC  
465 protein was measured by performing enzyme-linked immunosorbent assay  
466 (ELISA) at 24 h after the addition of Fn Sup (n=3). (B) The mRNA level of  
467 MUC5AC expression at 10 h after the addition of Fn Sup was analyzed by  
468 RT-PCR (n = 3). Data are expressed as the mean and SEM for 3 experiments.

469 An asterisk and a dagger indicate P values of <0.05 and <0.01, respectively,  
470 for comparison with modified GAM stimulation.

471

472 Fig. 2. Time-dependent effect of *Fusobacterium nucleatum* culture  
473 supernatant (FnSup) on MUC5AC synthesis. NCI-H292 cells were  
474 stimulated with modified GAM medium (1:64 dilution), or Fn Sup (dilution  
475 ratio,1:64). (A) MUC5AC protein was measured by an enzyme-linked  
476 immunosorbent assay (ELISA) (n = 4). (B) The mRNA level of MUC5AC  
477 expression after the addition of Fn Sup was analyzed by RT-PCR (n = 3).  
478 Data are expressed as the mean and SEM for the experiments. An asterisk  
479 and a dagger indicate P values of <0.05 and <0.01, respectively, for  
480 comparison with 0 h.

481

482 Fig. 3. Time-dependent phosphorylation of ERK 1/2, p38, and I $\kappa$ B after  
483 modified GAM broth stimulation (control) (A), and *Fusobacterium*  
484 *nucleatum* culture supernatant (FnSup) stimulation (B). Cells were treated  
485 with control/Fn Sup for each time and evaluated by Western blotting.  
486 ERK1/2 phosphorylation was induced 120 min after stimulation with Fn Sup,

487 and reached its maximum at 240 min after stimulation. The control  
488 stimulation induced ERK1/2 phosphorylation induced by the control was  
489 maximal at 480 min after stimulation. p38 and I $\kappa$ B phosphorylation was not  
490 evident in both stimulations. Data are representative of 3 separate  
491 experiments.

492

493 Fig.4. Effect of MAP kinase inhibitor on MUC5AC production in cells  
494 activated by *Fusobacterium nucleatum* culture supernatant (FnSup). Cells  
495 were pretreated with U0126 (ERK), SB203580 (p38 MAP kinase), and CAPE  
496 (NF  $\kappa$  B) 30min before Fn Sup stimulation. All the inhibitors effectively  
497 suppressed the MUC5AC protein production compared with the Fn Sup  
498 stimulation alone. Data are expressed as the mean and SEM for 4  
499 experiments. An asterisk and a dagger indicate P values of <0.05 and <0.01,  
500 respectively, for comparison with control (modified GAM stimulation).

501

502 Fig.5. Effects of azithromycin (AZM), clarithromycin (CAM), clindamycin  
503 (CLDM), and metronidazole (MTZ) on MUC5AC production induced by  
504 *Fusobacterium nucleatum* culture supernatant (FnSup). Cells were treated

505 with 1 to 100 µg of each drug. (CAM for 1 to 50 µg/mL; As maximal dose of  
506 CAM diluted in DMSO was available for 50 µg/mL) CAM and AZM  
507 dose-dependently suppressed Fn Sup-induced MUC5AC production. CLDM  
508 significantly suppressed Fn Sup-induced MUC5AC production only with 100  
509 µg/mL, while MTZ presented no reduction of MUC5AC at any concentration.  
510 Data are expressed as the mean and SEM for 4 experiments. An asterisk and  
511 a dagger indicate P values of <0.05 and <0.01, respectively, for comparison  
512 with Fn Sup stimulation alone.

513

514 Fig.6. Effects of azithromycin (AZM), clarithromycin (CAM), clindamycin  
515 (CLDM), and metronidazole (MTZ) on MUC5AC mRNA expression induced  
516 by *Fusobacterium nucleatum* culture supernatant (FnSup). Cells were  
517 treated with 100 µg of each drug (CAM for 50 µg/mL). CAM and AZM  
518 significantly suppressed Fn Sup-induced MUC5AC mRNA expression. Data  
519 are expressed as the mean and SEM for 5 experiments (n=3 for control). An  
520 asterisk and a dagger indicate P values of <0.05 and <0.01, respectively, for  
521 comparison with Fn Sup stimulation alone.

522

523 Fig. 7. Effects of macrolides, clindamycin, (A) and metronidazole (B) on ERK  
524 phosphorylation. Cells were stimulated with *Fusobacterium nucleatum*  
525 culture supernatant (Fn Sup) concurrently with each drug of maximal  
526 concentration (50 µg/mL for CAM, 100 µg/mL for AZM, CLDM, and MTZ),  
527 and evaluated 360 min after the stimulation. Equal amounts of protein  
528 were analyzed. Macrolide inhibited the detection levels of phosphorylation  
529 of ERK when compared to stimulation alone. Data are representative of 3  
530 separate experiments.

Fig. 1




Fig. 1. Dose-dependent effect of *Fusobacterium nucleatum* culture supernatant (FnSup) on MUC5AC synthesis. Confluent NCI-H292 cells were stimulated with modified GAM medium (1:9 dilution), or various concentrations of Fn Sup (dilution ratio, from 1:319 to 1:9). (A) MUC5AC protein was measured by an enzyme-linked immunosorbent assay (ELISA) at 24 h after the addition of Fn Sup. (B) The mRNA level of MUC5AC expression at 10 h after the addition of Fn Sup was analyzed by RT-PCR. Data are expressed as the mean and SEM for three experiments. An asterisk and a dagger indicate P values of <0.05 and <0.01, respectively, for comparison with modified GAM stimulation.

Fig. 2





Fig. 2. Time-dependent effect of *Fusobacterium nucleatum* culture supernatant (FnSup) on MUC5AC synthesis. NCI-H292 cells were stimulated with modified GAM medium (1:64 dilution), or Fn Sup (dilution ratio, 1:64). (A) MUC5AC protein was measured by an enzyme-linked immunosorbent assay (ELISA) (n=4). (B) The mRNA level of MUC5AC expression after the addition of Fn Sup was analyzed by RT-PCR (n=3). Data are expressed as the mean and SEM for the experiments. An asterisk and a dagger indicate P values of <0.05 and <0.01, respectively, for comparison with 0 h.



Fig. 3.

A)



B)




Fig. 3. Time-dependent phosphorylation of ERK 1/2, p38, and IκB after modified GAM broth stimulation (control) (A), and *Fusobacterium nucleatum* culture supernatant (FnSup) stimulation (B). Cells were treated with control/ Fn Sup for each time and evaluated by Western blotting. ERK1/2 phosphorylation was induced 120 min after stimulation with Fn Sup, and maximal at 240 min after stimulation. The control stimulation induced ERK1/2 phosphorylation induced by the control was maximal at 480 min after stimulation. p38 and IκB phosphorylation was not evident in both stimulation. Data are representative of three separate experiments.

Fig. 4.




Fig. 4. Effect of MAP kinase inhibitor on MUC5AC production in cells activated by *Fusobacterium nucleatum* culture supernatant (FnSup). Cells were pretreated with U0126 (ERK), SB203580 (p38 MAP kinase), PD98059 (ERK1/2), and CAPE (NFκB) 30min before Fn Sup stimulation. All the inhibitor effectively suppressed the MUC5AC protein production compared with the Fn Sup stimulation alone. Data are expressed as the mean and SEM for four experiments. An asterisk and a dagger indicate P values of <0.05 and <0.01, respectively, for comparison with control (modified GAM stimulation).

Fig. 5.




Fig.5. Effects of azithromycin (AZM), clarithromycin (CAM), clindamycin (CLDM), and metronidazole (MTZ) on MUC5AC production induced by *Fusobacterium nucleatum* culture supernatant (FnSup). Cells were treated with 1 to 100 $\mu\text{g}$  of each drugs. ( CAM for 1 to 50 $\mu\text{g/ml}$  ; As maximal dose of CAM diluted in medium was available for 50 $\mu\text{g/ml}$ ) CAM and AZM dose-dependently suppressed Fn Sup-induced MUC5AC production. CLDM significantly suppressed Fn Sup-induced MUC5AC production only with 100  $\mu\text{g/ml}$ , while MTZ had no reduction at any concentration. Data are expressed as the mean and SEM for four experiments. An asterisk and a dagger indicate P values of <0.05 and <0.01, respectively, for comparison with Fn Sup stimulation alone.

Fig. 6




Fig.6. Effects of azithromycin (AZM), clarithromycin (CAM), clindamycin (CLDM), and metronidazole (MTZ) on MUC5AC mRNA expression induced by *Fusobacterium nucleatum* culture supernatant (FnSup). Cells were treated with 100µg of each drugs. ( CAM for 50µg/mL) CAM and AZM significantly suppressed Fn Sup-induced MUC5AC mRNA expression. Data are expressed as the mean and SEM for five experiments (n=3 for control). An asterisk and a dagger indicate P values of <0.05 and <0.01, respectively, for comparison with Fn Sup stimulation alone.

Fig. 7




Fig.7. Effects of macrolides, clindamycin, (A) and metronidazole (B) on ERK phosphorylation. Cells were stimulated with *Fusobacterium nucleatum* culture supernatant (Fn Sup) concurrently with each drug of maximal concentration (50 $\mu$ g/mL for CAM, 100 $\mu$ g/mL for AZM, CLDM, and MTZ), and evaluated 360 min after the stimulation. Equal amounts of protein were analyzed. Macrolide inhibited the detection levels of phosphor-ERK when compared to stimulation alone. Data are representative of three separate experiments.